A number of trials, such as the DIAMOND (NCT03190694) and DAPA-CKD (NCT03036150), are currently ongoing to investigate the efficacy and safety of SGLT-2 inhibitors in patients with non-diabetic CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.